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Abstract
Retroviruses, hepadnaviruses, and some other retroelements are vulnerable to editing by single
stranded DNA cytidine deaminases. Of the eleven human genes encoding such enzymes, eight have
demonstrable enzymatic activity. Six of seven human APOBEC3 are able to hyperedit HBV DNA,
frequently on both strands. Although human APOBEC1 (hA1) is not generally expressed in normal
liver, hA1 can edit single stranded DNA in a variety of experimental assays. The possibility of
ectopic expression of hA1 in vivo cannot be ruled out and interestingly, transgenic mice with A1
expressed under a liver specific promoter develop hepatocellular carcinoma. The impact of hA1 on
HBV in tissue culture is varied with reports noting either reduced DNA synthesis or not, with
cytidine deamination taking a low profile. We sought to examine the hA1 editing activity on
replicating HBV. Using highly sensitive 3DPCR it was possible to show that hA1 edits the HBV
minus DNA strand as efficiently as hA3G, considered the reference deaminase for HIV and HBV.
The dinucleotide specificity of editing was unique among human cytidine deaminases providing a
hallmark of use in a posteriori analyses of in vivo edited genomes. Analysis of sequences derived from
the serum of two chronic carriers, indicated that hA1 explained only a small fraction of edited HBV
genomes. By contrast, several human APOBEC3 deaminases were active including hA3G.
Findings
Despite being the prototypic human cytidine deaminase,
human APOBEC1 (hA1) first identified in 1995 has been
overshadowed by other paralogs, notably activation
induced cytidine deaminase (AICDA) and the APOBEC3
gene cluster at ch22q13.1 [1-3]. Human A1 (hA1) edits a
single cytidine residue in human apolipoprotein B (apoB)
mRNA, a specificity that is conferred by its major interac-
tor, ACF, its expression being confined to intestinal epi-
thelial cells [4,5]. By contrast, the mouse, rat, dog and
horse A1s are expressed in the intestine and other organs
including the liver [2,6,7]. This situation is probably due
to an Alu insertion in a part of the hA1 gene inactivating a
generalist promoter [8,9]. RNA editing specificity can
break down in rabbit A1 transgenic mice where hyperedit-
ing of the apoB mRNA was described [10] and subse-
quently noted in normal mouse intestinal tissues [11]. For
transgenic mice expressing the rabbit APOBEC1 gene
under the control of a liver specific promoter, hepatic dys-
plasia and hepatocellular carcinomas were found [12].
Whether this is due to RNA or DNA editing is unknown
although in an E. coli DNA mutator assay, hA1 was highly
mutagenic meaning that the latter cannot be ruled out
[13]. It turned out that human and mouse/rat A1 enzymes
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are not true orthologs in that the rodent enzymes can
hyperedit both RNA and DNA, unlike hA1 that can only
deaminate ssDNA [13]. By contrast AICDA and the
human APOBEC3 (hA3) show an exclusive single
stranded DNA substrate specificity [14-27].
As retroviruses and hepadnaviruses replicate via a single
stranded cDNA intermediate, it is not surprising that
some are vulnerable to the effects of these cytidine deam-
inases if expressed in the target cell. While there is a huge
literature on the interaction between human immunode-
ficiency virus (HIV) and the hA3 cluster of genes (the hA3
genes), most of them can also edit hepatitis B virus (HBV)
DNA [28-33]. The role of A1 genes on retroviral replica-
tion is somewhat checkered. One report has shown that
HBV replication is restricted by hA1 yet doesn't address
the question of editing [34]. By contrast, another study
shows that the rat A1 deaminase hardly impacts HBV rep-
lication, even though a little cytidine deamination was
found [30]. Both hA1 and rat A1 impact HIV replication
in single cycle growth assays [35]. In the mouse A1 hardly
restricts Friend murine leukemia virus replication,
although using highly sensitive 3DPCR hypermutants
were recovered from a small fraction of cultured cells or
splenocytes from infected mice [11].
We sought to investigate the editing capacity of hA1 on
HBV replication using 3DPCR [28,31,32]. An infectious
molecular clone of HBV was transfected into quail QT6
cells with hA1 along with human APOBEC2 (hA2) and
human APOBEC3G (hA3G) as negative and positive con-
trols. QT6 cells were used so as to eliminate the endog-
enous APOBEC background typical of mammalian and
human cell lines [28]. At 72 h culture supernatants and
cell lysates were recovered. Western blotting of whole cell
lysates showed that all three APOBEC constructs were pro-
duced without obvious degradation (Figure 1A), the levels
of hA1 and hA3G being particularly comparable. Using
SYBR green quantification of HBV DNA, when normal-
ized to the empty expression vector transfection control,
hA1 and hA3G clearly impacted DNA replication (Figure
1B). PCR was performed on the HBV X gene using a con-
ventional two-step procedure as previously described
[28,31]. Amplification performed using a 95°C denatura-
tion temperature recovered HBV DNA in all samples,
apart from the negative DNA control (Figure 1C). When
3DPCR was performed on these PCR products at the
restricting temperature of 88.7°C, DNA was recovered
only from the hA1 and hA3G transfections (Figure 1C).
Cloning and sequencing of 24 clones identified so-called
G->A hypermutants indicative of genetic editing of the
minus DNA strand or cDNA, the frequency distribution of
edited genomes per sequence being generally comparable
(Figure 1D). No C->T hypermutants, indicative of plus
strand editing, were recovered. The mutation matrices
(Figure 1E) and editing frequencies were strictly compara-
ble, hA1 32% (range 16-52%) while that for hA3G was
34% (range 25-41%). In short, hA1 is every bit as efficient
as hA3G in editing HBV DNA.
As the dinucleotide context of editing is frequently a hall-
mark of different deaminases, for example hA3G shows a
strong preference for CpC, while hA3H prefers TpC, the
hA1 edited genomes were so analyzed. As can be seen
from Figure 1F, hA1 showed a strong preference for TpC
and a strong aversion for GpC. It was neutral with respect
to ApC. All other hA3 deaminases (hA3s) either avoid
GpC and ApC or are neutral (hA3A, hA3C, [28]). Hence,
along with the preference for TpC, this feature is highly
distinctive of hA1 editing.
Of course in vivo, one or more APOBEC deaminases could
be operative, either in different HBV infected cells or even
within the same cell. Hence global dinucleotide analyses
of edited genomes from patients might be misleading.
Comparative analysis of the dinucleotide contexts for
individual in vivo hyperedited sequences with reference
sets derived from transfections with individual hA1 or
hA3 genes should help highlight those deaminases opera-
tive in vivo. The only exception would be if two different
hA3 enzymes were packaged in the same virion. As can be
seen plotting the number of edited TpC vs. CpC sites
allows a clear distinction between hA1 and hA3G edited
sequences (Figure 2A). The same is true for GpC vs. ApC
(Figure 2B), although the number of deaminated bases is
far fewer, meaning that the observation is a little less
robust. The distinction between hA1 and hA3G could be
emphasized by analyzing TpC+ApC (unique to hA1) vs.
GpC+CpC (Figure 2C).
We have previously reported hA3 editing of HBV genomes
from sera derived from two chronically infected patients
with high viremia (> 109 DNA copies/ml, [31]). Single
molecule analysis of these sequences showed that there
was more overlap between the patient data "clouds" than
with that of hA3G. Although the individual dinucleotide
analyses might suggest that a few genomes are edited by
hA1 in vivo (Figures 2D, E vs. 2A, B), the combined dinu-
cleotide analysis (Figure 2C vs. 2F) showed no overlap
with the hA1 edited sequence set. We have previously
shown that the dinucleotide bias for individual hA3
deaminases varies with the base composition of the locus
[28]; hence, it is not possible to extend the analysis to
other edited regions of the HBV genome.
As ~20 hypermutated sequences were derived from each
of the sera, the resolution of the argument is ~5%. Obvi-
ously with 10 times more patient sequences it might be
able to find bona fide evidence of a little hA1 editing. By
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58% respectively for patients 130.71 and 12763). Accord-
ingly, other hA3 deaminases must be involved; yet given
the similarities between the editing contexts of hA3A,
hA3B and hA3C, it is not possible to be more precise. Fur-
thermore, chronic hepatitis shows many facets; and
although hA1 expression is confined to the intestinal epi-
thelium and not the liver [6], its expression profile in a
variety of different clinical presentations including highly
inflamed cirrhotic tissue is not known.
As mentioned above, hA1 transgenic mice under the con-
trol of the liver specific apoE promoter presented with
hepatic dysplasia and ultimately liver cancer; thus, the
role of cytidine deamination remains open. Even though
hA1 does not edit HBV at a high frequency, because hA1
can shuttle between the cytoplasm and nucleus, it is
potentially a more likely pro-cancerous candidate than
hA3G, which is strictly cytoplasmic.
Human APOBEC1 can efficiently hyperedit HBV minus strand DNA Figure 1
Human APOBEC1 can efficiently hyperedit HBV minus strand DNA. A) Western blotting of V5 tagged hA1, hA2 and 
hA3G cDNA constructs. Molecular weight markers (kDa) are given to the left. B) Reduction of HBV DNA production follow-
ing cotransfection of QT6 cells with HBV ± hA1 ± hA3G. C) PCR and 3DPCR of HBV X region DNA from transfections. C-, 
no DNA control; C+, HBV alone; pv, plasmid vector control; hA1, V5-tagged human APOBEC1 expression plasmid; hA2, V5 
tagged human APOBEC2; hA3G, V5-tagged human APOBEC3G as positive control. M, molecular weight markers. The sizes of 
the PCR and 3DPCR fragments are 314 and 213 bps. D) Frequency distribution of G->A hypermutants in terms of mutations 
per clone. E) Mutation matrices of 24 hA1 and hA3G hyperedited HBV sequences. The size of the locus is 167 bp. F) Dinucle-
otide analysis of hA1 and hA3G edited HBV genomes. A 2 analysis showed that frequencies for hA1 and hA3G deviated signif-
icantly from the expected values as indicated by asterisks (p < 0.001).
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Abbreviations
3DPCR: Differential DNA denaturation PCR; ACF:
APOBEC1 complementary factor; hAICDA: Human acti-
vation induced cytidine deaminase; hAPOBEC1, hA1:
Human apolipoprotein B editing complex protein 1;
hAPOBEC2, hA2: Human apolipoprotein B editing com-
plex protein 2; hAPOBEC3, hA3: Human apolipoprotein
B editing complex protein 3; hAPOBEC3A-H, hA3A-H:
Human apolipoprotein B editing complex protein 3 pro-
teins A to H; HBV: Hepatitis B virus; HIV-1: Human
Immunodeficiency virus type 1.
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